Posted on August 1, 2017
Bristol-Meyers Squibb’s Opdivo (nivolumab) has just been approved by the FDA for patients with a microsatellite instability-high tumors (also known as MSI-H) or mismatched repair deficiency (dMMR). The approval was specifically for patients whose cancer has progressed following Fluoropyrimidine, Oxaliplatin, and Irinotecan.
Opdivo joins Merck’s Keytruda (pembrolizumab) as the second immunotherapy drug to be approved within four months. Here’s what you need to know. Read more
Posted on July 27, 2017
We can’t thank you enough for your support of the Undy Run/Walk and that’s why we wanted you to be the first to know about the latest and greatest Undy Participant enhancement! Read more
Posted on July 21, 2017
This past June Colon Cancer Alliance staff members attended the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Each year oncology professionals from around the world attend this conference and present the latest and greatest in cancer research and treatment. Read more
Posted on June 27, 2017
The revolution has officially begun.
With Keytruda, we see a drug that treats different kinds of cancer with the same genetic profile. This is called being tumor agnostic. In short, it doesn’t matter where your tumor is located (colon, breast, lung, etc.), but what genetic markers it contains.
This has the potential to radically change how we see and treat cancers. Read more
Posted on June 10, 2017
Running 13.1 miles wouldn’t qualify as fun for most people, but Jessica Tsay isn’t your usual runner. While she’s developed a love for running over time, her passion for colon cancer came only recently after her mom was diagnosed in February. We’re excited to have Jessica running with Team Colon Cancer Alliance at the Rock ‘n’ Roll in Seattle next weekend. Her goal is to not just raise money, but to motivate others to get screened and take charge of their health! Good luck, Jessica and thank you for all you’re doing to support your mom and patients across the country with every mile! Read more